The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Clinical Cancer Research|2015Cited by 18
Supplementary Figure S5 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Theodoros P. Vassilakopoulos et al.|Unknown|2023Cited by 0
Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) StudyT C, David Oscier, Sofia Chatzileontiadou et al.|Blood|2024Cited by 0
Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.Thomas Chatzikonstantinou, Anna Puiggros, Persefoni Talimtzi et al.|Blood|2025Cited by 0